EPO biomarkers Market Trends 2018 | Segmentation, Outlook, Industry Report to 2023

Erythropoietin (EPO) is a hormone that is produced from the kidney inside the human body. EPO biomarkers Market are used to increase the growth of red blood cells in the body by stimulating the bone marrow. Some of the EPO biomarkers available in the market are epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, recombinant human erythropoietin, and darbepoetin alfa. Erythropoietin alfa is used to treat anemia and cancer cells and it increases the count of red blood cells in the body. Erythropoietin is mostly administered as an alternative to iron supplements. Moreover, the erythropoietin biomarkers are used to treat end-stage renal diseases (ESRD), and anemia induced from multiple myeloma, cancer, and AIDS associated anemia.

Request a Free Sample of our EPO biomarkers Market: https://www.omrglobal.com/request-sample/epo-biomarkers-market

Major factors contributing to the growth of the global EPO biomarkers market include increasing sedentary lifestyle and faulty dietary habits has increased the prevalence of cancers and chronic kidney diseases in the emerged economies. Moreover, the increasing incidence of end-stage renal disorders and hematological diseases is further increasing the demand for EPO biomarkers. The patent expiration of EPO biomarkers is significantly increasing the introduction of novel EPO biomarkers in the market. However, the lack of quality control testing laboratories in emerging economies such as India and China is a major factor hindering the growth of the market. Improper price capping regulations across the globe is another factor that is significantly responsible in hampering the growth of the global EPO biomarkers market. However, the favorable healthcare regulations in emerged economies such as the U.S. and rising prevalence of chronic diseases such as cancer is expected to fuel the market growth in the near future.

The EPO Biomarkers Market can be segmented on the basis of biomarker type, applications, and end users. Based on biomarker type, the market is segmented into erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, recombinant human erythropoietin, and darbepoietin alfa. Based on application, the market is bifurcated into end-stage renal disorder, cancers, rheumatoid arthritis, AIDS, myelodysplastic syndrome, neurology, hematology, and others (anaemia of chronic inflammatory syndromes). Based on end users, the market is segmented into diagnostic centers, ambulatory care and surgical centers, and hospitals. Among biomarker type, the erythropoietin alfa segment holds a major share in the global EPO biomarkers market. This is owing to increasing adoption in the treatment of chronic renal disorders and cancer.
The global EPO biomarkers market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global EPO biomarkers market, followed by Europe. This is mainly owing to the developed healthcare infrastructure in the region. Moreover, the systematic initiatives taken by the government in the research and development activities is one of the major factors contributing in the growth of the EPO biomarkers market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are low cost of treatment therapy and increasing incidence rate of hematological diseases in the region, especially in India, China, Pakistan, and Bangladesh.

A full Report of EPO biomarkers Market is Available at: https://www.omrglobal.com/industry-reports/epo-biomarkers-market

EPO biomarkers MARKET SEGMENTATION

BY BIOMARKERTYPE
•
ERYTHROPOIETINALFA
ERYTHROPOIETINBETA
ERYTHROPOIETINZETA
ERYTHROPOIETINTHETA
RECOMBINANTHUMANERYTHROPOIETIN
DARBEPOIETINALFA

BYAPPLICATIONS
•
END-STAGERENALDISORDER
CANCERS
RHEUMATOIDARTHRITIS
AIDS
MYELODYSPLASTICSYNDROME
NEUROLOGY
HEMATOLOGY
OTHERS (ANAEMIA OF CHRONIC INFLAMMATORY SYNDROMES)
BYENDUSERS
DIAGNOSTICCENTERS
AMBULATORYCAREANDSURGICALCENTERS
HOSPITALS
•
COMPETITIVELANDSCAPE
•
KEYMARKETSTRATEGIES
KEYCOMPANYANALYSIS
REGIONALANALYSIS
•
NORTHAMERICAN
UNITEDSTATES
CANADA
EUROPE
U.K
GERMANY
ITALY
SPAIN
FRANCE
ROE
ASIAPACIFIC
INDIA
CHINA
JAPAN
ROAPAC
REST OF THE WORLD
COMPANYPROFILES
•
3SBIOGROUP
AGILENTTECHNOLOGIES, INC.
AMGENINC.
BIOAGILYTIXLABS
BIOCON
BIO-RADLABORATORIES, INC.
EVETECHNOLOGIES
F. HOFFMANN-LAROCHELTD
GALENICAAG
GENSCRIPT
GLAXOSMITHKLINEPLC.
INTASPHARMACEUTICALSLTD.
JOHNSON&JOHNSONSERVICES, INC.
KYOWAHAKKOKIRINCO., LTD.
LGLIFESCIENCESPVTLTD
MERCKKGAA
MYRIADRBM
NOVARTISAG
PACIFICBIOMARKERS
PFIZERINC.
SANDOZINTERNATIONALGMBH
SHANDONGKEXING
SIEMENSAG
THERMO FISHER SCIENTIFIC

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/epo-biomarkers-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based service

This release was published on openPR.